Journal article
A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
Authors
Chiappori AA; Ellis PM; Hamm JT; Bitran JD; Eiseman I; Lovalvo J; Burnett D; Olson S; Lenehan P; Zinner RG
Journal
Journal of Thoracic Oncology, Vol. 1, No. 9, pp. 1010–1019
Publisher
Elsevier
Publication Date
January 1, 2006
DOI
10.1097/01243894-200611000-00015
ISSN
1556-0864
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, OralAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleEvaluation Studies as TopicFemaleHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedMorpholinesNeoplasm InvasivenessNeoplasm StagingNeutropeniaOdds RatioPaclitaxelPatient SelectionProbabilityPrognosisRisk AssessmentSingle-Blind MethodSurvival AnalysisTreatment OutcomeUnited States